45 results about "Very Low-Density Lipoprotein Receptor" patented technology

Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and / or C1 and / or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.

A method for making hepatocytes from extrahepatic somatic stem cells comprises: a) culturing somatic stem cells in a medium comprising hepatic growth factor to cause the stem cells to differentiate toward hepatocytes; b) culturing cells from a) in a medium comprising HGF and oncostatin M to facilitate the cell differentiation toward hepatocytes; and c) culturing cells from b) in a medium comprising oncostatin M to cause the differentiated cells to mature into hepatocytes, thereby producing a cell population that has morphological features of hepatocytes and at least four of the following characteristics: i) antibody-detectable expression of albumin; ii) real-time reverse transcriptase-polymerase chain reaction-detectable expression of α-fetoprotein, HNF-1α, HNF-3β, HNF-4, HNF-6, α1-antitrypsin, alkaline phosphatase, tryptophan 2,3-dioxygenase, tyrosine aminotransferase, cytochrome P450 family 2 subfamily E polypeptide 1, glutamine synthetase, and / or low density lipoprotein receptor; iii) urea secretion; iv) cytochrome p450 enzyme activity; v) glycogen storage; and vi) low density lipoprotein uptake.

The present invention relates to reagents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the present invention relates to the use of proteins encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin-like protein (SYPL), stomatin-like 2 (STOML2), Ras-associated GTP-binding protein (RAGA), nucleotide-sensitive Chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide-binding protein β2-like 1 (GNB2L1), guanine nucleotide-binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low-density lipoprotein receptor-related protein 4 (LRP4), human kidney Nucleic acid and amino acid sequences of glomerular epithelin 1 (GLEPP1), toll-like receptor 3 (TLR3), and / or zona pellucida glycoprotein 3A (ZP3) for early and advanced non-steroid-specific cancer diagnosis, cancer prognosis, and For screening therapeutic agents that modulate the gene expression and / or biological activity of the protein. The invention further relates to biotechniques designed to inhibit gene expression and / or biological activity of said proteins, including the use of agents identified in the screening assays described herein, vector delivery of antisense polynucleotide sequences, and the Antibody targeting the protein. In specific embodiments, the protein is of human origin.

The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.

The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.

The invention relates to a preparation method of anti-atherosclerosis active laminarins,Which comprises the following steps: 1. washing Laminaria digitata; 2. removing water from the Laminaria digitata; 3. preparing Laminaria digitata powder; 4. extracting laminarins; 5. removing alginates; 6. removing proteins; and 7. precipitating the laminarins. The extraction solvent is distilled water instead of acid liquor or alkali liquor in the traditional technique, thereby greatly lowering the equipment corrosion and environmental pollution caused by acid liquor or alkali liquor in the production process; the laminarin component A and the laminarin component B prepared by the method provided by the invention have strong anti-atherosclerosis activity; and compared with the model set, the inhibition rates of the laminarin component A and the laminarin component B for low-density lipoprotein acceptor defect type mouse endarterium lipidosis are respectively up to 75% and 87%, which indicates that water-soluble laminarins are the material basis of Laminaria digitata for displaying anti-atherosclerosis activity.